Atyr Pharma Inc (ATYR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,792 | -74,123 | -60,159 | -34,413 | -14,881 |
| Depreciation Amortization | 139 | -301 | -334 | -211 | -140 |
| Other Working Capital | -3,171 | 7,453 | 6,913 | 2,827 | -1,577 |
| Other Operating Activity | 1,307 | 4,985 | 3,790 | 2,483 | 1,178 |
| Operating Cash Flow | $-12,517 | $-61,986 | $-49,790 | $-29,314 | $-15,420 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 11,632 | -4,988 | -21,450 | -1,110 | -4,420 |
| PPE Investments | -138 | -65 | -46 | -9 | N/A |
| Investing Cash Flow | $11,494 | $-5,053 | $-21,496 | $-1,119 | $-4,420 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -142 | -539 | -400 | -264 | -131 |
| Common Stock Issued | N/A | 66,550 | 66,542 | 36,789 | 18,759 |
| Financing Cash Flow | $-142 | $66,011 | $66,142 | $36,525 | $18,628 |
| Beginning Cash Position | 12,978 | 14,006 | 14,006 | 14,006 | 14,006 |
| End Cash Position | 11,813 | 12,978 | 8,862 | 20,098 | 12,794 |
| Net Cash Flow | $-1,165 | $-1,028 | $-5,144 | $6,092 | $-1,212 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,517 | -61,986 | -49,790 | -29,314 | -15,420 |
| Capital Expenditure | -138 | -77 | -46 | -9 | N/A |
| Free Cash Flow | -12,655 | -62,063 | -49,836 | -29,323 | -15,420 |